Knm Pharma Profile
Key Indicators
- Authorised Capital ₹ 9.65 Cr
as on 30-07-2024
- Paid Up Capital ₹ 4.63 M
as on 30-07-2024
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.53 Cr
as on 30-07-2024
- Satisfied Charges ₹ 6.37 Cr
as on 30-07-2024
- Revenue 106.29%
(FY 2023)
- Profit 76.91%
(FY 2023)
- Ebitda 3.80%
(FY 2023)
- Net Worth 2.53%
(FY 2023)
- Total Assets 88.87%
(FY 2023)
About Knm Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.65 Cr and a paid-up capital of Rs 4.63 M.
The company currently has active open charges totaling ₹8.53 Cr. The company has closed loans amounting to ₹6.37 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kalyansingh Rana, Jatubha Rana, Jayveersinh Rana, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2010PTC060512
- Company No.
060512
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Apr 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Knm Pharma Private Limited offer?
Knm Pharma Private Limited offers a wide range of products and services, including Diclofenac, Diclofenac Paracetamol Tablet, Mineral Supplement, Calcium Tablet, Vitamin Tablets & Capsules, Vitamin D Tablets, Nutraceuticals & Dietary Supplements, Antibiotic Tablets & Capsules, Azithromycin Tablets.
Who are the key members and board of directors at Knm Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayveersinh Rana  | Director | 25-Mar-2022 | Current |
| Kalyansingh Rana | Director | 25-Mar-2022 | Current |
| Jatubha Rana | Director | 25-Mar-2022 | Current |
| Vishwajitsinh Rana | Director | 25-Mar-2022 | Current |
Financial Performance of Knm Pharma.
Knm Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 106.29% increase. The company also saw a substantial improvement in profitability, with a 76.91% increase in profit. The company's net worth moved up by a moderate rise of 2.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Knm Pharma?
In 2023, Knm Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ciphem Pharma Private LimitedActive 1 year 6 months
Jatubha Rana and Vishwajitsinh Rana are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Mar 2023 | ₹3.25 Cr | Open |
Others Creation Date: 28 Mar 2023 | ₹1.00 Cr | Open |
Others Creation Date: 27 Mar 2023 | ₹4.25 Cr | Open |
How Many Employees Work at Knm Pharma?
Knm Pharma has a workforce of 2 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Knm Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Knm Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
